



Press Release

October 26, 2026

New EU-MDR compliant light cure adhesives designed for future-ready medical device manufacturing

Henkel introduces next-generation light cure adhesives for medical device assembly

Düsseldorf – Henkel Adhesive Technologies today announced the launch of five next-generation light cure medical device adhesives: Loctite AA 3914, AA 3915, AA 3917, AA 3937 and AA 3964. Formulated in line with EU-MDR ED, CMR & TPO requirements¹ and developed for medical device assembly, the new portfolio is designed to help manufacturers address evolving regulatory needs while maintaining high-performance bonding.

In addition to regulatory readiness, the new medical device adhesives introduce several feature improvements, including enhanced fluorescence stability before and after cure to support in-line visual inspection, as well as improved strength retention during accelerated aging testing to support long-term device performance and validation requirements.

Medical device manufacturers are increasingly evaluating materials used throughout device design and manufacturing as regulatory requirements continue to evolve. Medical Device Regulation (EU MDR 2017/745) places additional focus on substances classified as carcinogenic, mutagenic or toxic for reproduction (CMR) and endocrine disruptors (ED), prompting many manufacturers to review existing material selections and long-term compliance strategies.

Henkel's new portfolio of medical device adhesives was developed with these industry trends in mind. Formulated in line with EU-MDR ED, CMR & TPO requirements¹, the new grades

¹ EU MDR compliant in reference to Section 10.4. of EU MDR 2017/745; referring to the threshold of ED, CMR, TPO content; CMR = Carcinogenic, Mutagenic, or Reproductively hazardous ingredients, ED = Endocrine Disruptors, TPO = Trimethylbenzoyl Diphenylphosphine Oxide; All information, including any statement that the product is "designed for" specific applications, is provided for guidance only. To ensure suitability for your application, we recommend that you carry out sufficient own tests.

contain less than 0.1% by weight of CMR, ED and TPO-related content and have been tested according to ISO 10993-based Henkel protocols. The portfolio provides manufacturers with a range of medical device adhesive solutions designed to support future-ready assembly processes while continuing to meet demanding medical device performance requirements.

“At Henkel, we view innovation through the lens of our customers' challenges and opportunities. This new portfolio was developed with that objective in mind, helping medical device manufacturers navigate evolving regulatory needs while maintaining performance, reliability, and manufacturing efficiency, essential to their success. It represents another step in our ongoing commitment to supporting our customers' long-term growth and enabling the innovation that drives the next generation of medical devices,” said Julia Kurtz, Director Marketing & Strategy for Industrial Adhesives at Henkel.

The launch reflects Henkel's continued commitment to supporting the medical device industry with materials expertise, regulatory knowledge and application-focused innovation. As manufacturers navigate increasingly complex product development and regulatory environments, access to validated, high-performance assembly materials remain an important factor in reducing risk, supporting compliance efforts and accelerating innovation.

Henkel will present its new next-generation light cure medical device adhesives portfolio at

MD&M Midwest: October 28-29, 2026, in Minneapolis, MN, USA

COMPAMED: November 16-19, 2026, in Düsseldorf, Germany

The company's experts will be available during the shows to discuss regulatory considerations, validation planning and application-specific requirements for medical device assembly.

LOCTITE® is a registered trademark of Henkel and/or its affiliates in the USA, Germany and elsewhere.

About Henkel

With its brands, innovations and technologies, Henkel holds leading market positions worldwide in the industrial and consumer businesses. The business unit Adhesive Technologies is the global leader in the market for adhesives, sealants and coatings. With Consumer Brands, the company holds leading positions especially in laundry & home care and hair in many markets and categories around the world. The company's three strongest brands are Loctite, Persil and Schwarzkopf. In fiscal 2025, Henkel reported sales of about 20.5 billion euros and adjusted operating profit of around 3.0 billion euros. Henkel's preferred shares are listed in the German stock index DAX. Sustainability has a long tradition at Henkel, and the company has a clear sustainability strategy with specific targets. Henkel was founded in 1876 and today employs a diverse team of about 50,000 people worldwide – united by a strong corporate culture, shared values and a common purpose: "Pioneers at heart for the good of generations." More information at www.henkel.com

Photo material is available at www.henkel.com/press

Contact Sebastian Hinz
Phone +49 211 797-85 94
Email sebastian.hinz@henkel.com

Henkel AG & Co. KGaA



Henkel has launched next-generation light cure adhesives for medical device assembly.



The new Loctite portfolio is designed to help manufacturers address evolving regulatory needs while maintaining high-performance bonding.